Skip to main content

Advertisement

SpringerLink
Log in

Treatment of erosive osteoarthritis with peroxisome proliferator-activated receptor alpha agonist fenofibrate: a pilot study

  • Short Communication
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Hand osteoarthritis (HOA) is a common condition associated with high disease burden and frequently accompanied by comorbidities including dyslipidemia, atherosclerosis and obesity. The most debilitating HOA phenotype is erosive HOA (EHOA), characterized by synovial inflammation, formation of erosions, and substantial decline in hand function. Currently, there is no proven symptomatic treatment for the EHOA. Due to their broad spectrum effects directed on lipid metabolism, inflammation and pain, the agonists of peroxisome proliferator-activated receptor alpha or fibrates are a candidate class of drugs for the treatment of EHOA. In this study, we assessed the influence of fenofibrate treatment on clinical efficacy parameters, in vivo cytokine and adipokine production and concentrations of endothelial progenitor cells (EPC) in patients with EHOA. Fourteen patients received treatment with 145 mg of fenofibrate/day for 12 weeks. Fenofibrate treatment was associated with significant decreases in pain score, tender joint count, duration of morning stiffness, disease activity score, Cochin index, and ESR. Eight (57.14 %) patients developed Outcome Measures in Rheumatology Clinical Trials–Osteoarthritis Research Society response at the end of treatment. Paracetamol consumption did not change during the treatment course. There was a significant reduction in triglyceride levels. No changes were detected in serum pro-inflammatory cytokine and adipokine concentrations while circulating IL-10 levels significantly decreased. There were no differences in circulating EPC numbers before and after the treatment. Fenofibrate was well tolerated, no patient experienced disease flare during the treatment. In conclusion, in EHOA patients, fenofibrate is associated with pleiotropic effects on pain, inflammation, and lipid profile. Larger, controlled studies are needed to confirm these results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Anandarajah A (2010) Erosive osteoarthritis. Discov Med 9(48):468–477

    PubMed  Google Scholar 

  2. Gkretsi V, Simopoulou T, Tsezou A (2011) Lipid metabolism and osteoarthritis: lessons from atherosclerosis. Prog Lipid Res 50(2):133–140. doi:10.1016/j.plipres.2010.11.001

    Article  PubMed  CAS  Google Scholar 

  3. Shirinsky IV, Shirinsky VS (2011) Targeting nuclear hormone receptors: PPARalpha agonists as potential disease-modifying drugs for rheumatoid arthritis. Int J Rheumatol 2011:937843. doi:10.1155/2011/937843

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  4. Benameur T, Tual-Chalot S, Andriantsitohaina R, Martinez MC (2010) PPARalpha is essential for microparticle-induced differentiation of mouse bone marrow-derived endothelial progenitor cells and angiogenesis. PLoS One 5(8):e12392

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  5. Dimmeler S, Zeiher AM (2004) Vascular repair by circulating endothelial progenitor cells: the missing link in atherosclerosis? J Mol Med (Berl) 82(10):671–677. doi:10.1007/s00109-004-0580-x

    Article  Google Scholar 

  6. Belfort R, Berria R, Cornell J, Cusi K (2010) Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. J Clin Endocrinol Metab 95(2):829–836

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  7. Francois M, Richette P, Tsagris L, Fitting C, Lemay C, Benallaoua M, Tahiri K, Corvol MT (2006) Activation of the peroxisome proliferator-activated receptor alpha pathway potentiates interleukin-1 receptor antagonist production in cytokine-treated chondrocytes. Arthritis Rheum 54(4):1233–1245. doi:10.1002/art.21728

    Article  PubMed  CAS  Google Scholar 

  8. Oliveira AC, Bertollo CM, Rocha LT, Nascimento EB Jr, Costa KA, Coelho MM (2007) Antinociceptive and antiedematogenic activities of fenofibrate, an agonist of PPAR alpha, and pioglitazone, an agonist of PPAR gamma. Eur J Pharmacol 561(1–3):194–201. doi:10.1016/j.ejphar.2006.12.026

    Article  PubMed  CAS  Google Scholar 

  9. Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D, Brandt K, Brown C, Cooke TD, Daniel W, Gray R et al (1990) The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum 33(11):1601–1610

    Article  PubMed  CAS  Google Scholar 

  10. Poiraudeau S, Chevalier X, Conrozier T, Flippo RM, Liote F, Noel E, Lefevre-Colau MM, Fermanian J, Revel M, Rhumato R (2001) Reliability, validity, and sensitivity to change of the Cochin hand functional disability scale in hand osteoarthritis. Osteoarthr Cartil 9(6):570–577

    Article  PubMed  CAS  Google Scholar 

  11. Pham T, van der Heijde D, Altman RD, Anderson JJ, Bellamy N, Hochberg M, Simon L, Strand V, Woodworth T, Dougados M (2004) OMERACT–OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthr Cartil 12(5):389–399. doi:10.1016/j.joca.2004.02.001

    Article  PubMed  CAS  Google Scholar 

  12. Redondo S, Hristov M, Gordillo-Moscoso AA, Ruiz E, Weber C, Tejerina T (2008) High-reproducible flow cytometric endothelial progenitor cell determination in human peripheral blood as CD34+/CD144+/CD3− lymphocyte sub-population. J Immunol Methods 335(1–2):21–27

    Article  PubMed  CAS  Google Scholar 

  13. Kwok WY, Kloppenburg M, Rosendaal FR, van Meurs JB, Hofman A, Bierma-Zeinstra SM (2011) Erosive hand osteoarthritis: its prevalence and clinical impact in the general population and symptomatic hand osteoarthritis. Ann Rheum Dis 70(7):1238–1242. doi:10.1136/ard.2010.143016

    Article  PubMed  CAS  Google Scholar 

  14. Bijsterbosch J, Watt I, Meulenbelt I, Rosendaal FR, Huizinga TW, Kloppenburg M (2010) Clinical burden of erosive hand osteoarthritis and its relationship to nodes. Ann Rheum Dis 69(10):1784–1788. doi:10.1136/ard.2009.125435

    Article  PubMed  CAS  Google Scholar 

  15. Banks SE (2010) Erosive osteoarthritis: a current review of a clinical challenge. Clin Rheumatol 29(7):697–706. doi:10.1007/s10067-009-1369-7

    Article  PubMed  Google Scholar 

  16. Goto M (2010) A comparative study of anti-inflammatory and antidyslipidemic effects of fenofibrate and statins on rheumatoid arthritis. Mod Rheumatol 20(3):238–243

    Article  PubMed  CAS  Google Scholar 

  17. LoVerme J, Russo R, La Rana G, Fu J, Farthing J, Mattace-Raso G, Meli R, Hohmann A, Calignano A, Piomelli D (2006) Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J Pharmacol Exp Ther 319(3):1051–1061. doi:10.1124/jpet.106.111385

    Article  PubMed  CAS  Google Scholar 

  18. Cascao R, Moura RA, Perpetuo I, Canhao H, Sousa E, Mourao AF, Rodrigues AM, Polido-Pereira J, Queiroz MV, Rosario HS, Souto-Carneiro MM, Graca L, Fonseca JE (2010) Identification of a cytokine network sustaining neutrophil and Th17 activation in untreated early rheumatoid arthritis. Arthritis Res Ther 12(5):R196

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  19. Ward MM (2004) Relative sensitivity to change of the erythrocyte sedimentation rate and serum C-reactive protein concentration in rheumatoid arthritis. J Rheumatol 31(5):884–895

    PubMed  CAS  Google Scholar 

  20. Botter SM, van Osch GJ, Clockaerts S, Waarsing JH, Weinans H, van Leeuwen JP (2011) Osteoarthritis induction leads to early and temporal subchondral plate porosity in the tibial plateau of mice: an in vivo microfocal computed tomography study. Arthritis Rheum 63(9):2690–2699. doi:10.1002/art.30307

    Article  PubMed  Google Scholar 

  21. Saviola G, Abdi-Ali L, Campostrini L, Sacco S, Baiardi P, Manfredi M, Mannoni A, Benucci M (2012) Clodronate and hydroxychloroquine in erosive osteoarthritis: a 24-month open randomized pilot study. Mod Rheumatol 22(2):256–263. doi:10.1007/s10165-011-0506-8

    Article  PubMed  CAS  Google Scholar 

  22. Stunes AK, Westbroek I, Gustafsson BI, Fossmark R, Waarsing JH, Eriksen EF, Petzold C, Reseland JE, Syversen U (2011) The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats. BMC Endocr Disord 11:11. doi:10.1186/1472-6823-11-11

    Article  PubMed Central  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We would like to thank Dr. Irina Istranen, Novosibirsk Municipal Immunology Center, for her help in patient enrollment.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Laboratory of Clinical Immunopharmacology, Institute of Clinical Immunology RAMS, 6 Zalesskogo str., 630099, Novosibirsk, Russia

    Ivan V. Shirinsky & Valery S. Shirinsky

Authors
  1. Ivan V. Shirinsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Valery S. Shirinsky
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ivan V. Shirinsky.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shirinsky, I.V., Shirinsky, V.S. Treatment of erosive osteoarthritis with peroxisome proliferator-activated receptor alpha agonist fenofibrate: a pilot study. Rheumatol Int 34, 613–616 (2014). https://doi.org/10.1007/s00296-013-2766-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-013-2766-4

Keywords

Search

Navigation